cardiomyopathy

News

AZ, Ionis hit by unexpected Wainua trial failure

Prospects for AstraZeneca and Ionis' Wainua have been severely dented by a failed trial in ATTR cardiomyopathy, weighing on the shares of both firms.

News

New biotech Atrium born out of Novartis/Avidity marriage

Atrium Therapeutics has launched with $270m in funding and two preclinical siRNA candidates for rare genetic cardiomyopathies.

R&D

The diagnostic odyssey: Challenges and opportunities in tran...

Transthyretin amyloidosis (ATTR) is a rarely diagnosed and relentless disease that demands our attention.

News

Alnylam joins three-way contest in ATTR cardiomyopathy

Alnylam has claimed FDA approval for Amvuttra in ATTR cardiomyopathy, allowing it to compete with rival therapies from Pfizer and BridgeBio.

News

Capricor files cell therapy for DMD cardiomyopathy with FDA

Capricor completes its US filing for deramiocel, vying to become the first FDA-approved therapy for cardiomyopathy in Duchenne muscular dystrophy.

News

Alnylam hails vutrisiran data, but investors seem sceptical

Alnylam Pharma has been riding high since revealing top-line results from its HELIOS-B trial of vutrisiran in transthyretin-mediated amyloidosis (ATTR) – but a look at the full data seems t

AZ, Ionis hit by unexpected Wainua trial failure

New biotech Atrium born out of Novartis/Avidity marriage

The diagnostic odyssey: Challenges and opportunities in tran...

Alnylam joins three-way contest in ATTR cardiomyopathy

Capricor files cell therapy for DMD cardiomyopathy with FDA

Alnylam hails vutrisiran data, but investors seem sceptical

Lundbeck preps for key bexicaserin data around year-end

Discover a new era of healthcare panel engagement: Grounded ...

cardiomyopathy

Editor's Picks